Novartis AG

Recent news

• Novartis AG (NVS.US) secures approval in China for a new indication for its blockbuster radiopharmaceutical
  Zhitong Finance · 8/26
• TD Cowen Maintains Novartis AG(NVS.US) With Hold Rating, Raises Target Price to $180
  Market Newswire · 6/12
• TD Cowen Maintains Novartis AG(NVS.US) With Hold Rating, Maintains Target Price $180
  Market Newswire · 7/27
• BofA Securities Maintains Novartis AG(NVS.US) With Buy Rating, Raises Target Price to $177.37
  Market Newswire · 6/11
• SAAG CONSOLIDATED (M): Britac Berhad Disposal of 350,000 shares of HK$1.00 each representing 70% of the total issued and paid up share capital of Britac (China) Limited by Britac-Saag (S) Pte Ltd, a wholly owned subsidiary of Britac Berhad to NVS Invest &
  Bursa Malaysia · 4/22
• Argus Research Initiates Novartis AG(NVS.US) With Buy Rating, Announces Target Price $160
  Market Newswire · 6/6
• BofA Securities Maintains Novartis AG(NVS.US) With Buy Rating
  Market Newswire · 7/22
• SAAG CONSOLIDATED (M): Britac Berhad ("Britac") - Disposal of 350,000 shares of HK$1.00 each representing 70% of the total issued and paid up share capital of Britac (China) Limited by Britac-Saag (S) Pte Ltd, a wholly owned subsidiary of Britac to NVS
  Bursa Malaysia · 4/17
• BofA Securities Maintains Novartis AG(NVS.US) With Buy Rating, Announces Target Price $172.96
  Market Newswire · 9/1
• Strong sales of innovative drugs offset the impact from generics! Novartis AG (NVS.US) Q2 results beat expectations, signaling a return to growth trajectory.
  Zhitong Finance · 7/21

Headlines are aggregated automatically and are not independently verified or edited by our team.